BRIEF-Medicinova starts interim efficacy analysis in phase 2b trial of MN-166
July 13, 2016 at 06:56 AM EDT
* Medicinova announces initiation of interim efficacy analysis in phase 2b trial of MN-166 (ibudilast) in progressive MS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.